Lung cancer is a major global health problem, as it is the leading cause of cancer-related
deaths worldwide. Major advances in the identification of key mutational alterations have led …

Five-year survival rates for non–small cell lung cancer (NSCLC) range from 14% to 49% for
stage I to stage IIIA disease, and are< 5% for stage IIIB/IV disease. Improvements have been …

Lung cancer is the number one cause of cancer-related deaths. The malignancy is
characterized by dismal prognosis and poor clinical outcome mostly due to advanced-stage …

Lung cancer mortality has decreased over the past decade and can be partly attributed to
advances in targeted therapy and immunotherapy. Immune checkpoint inhibitors (ICIs) have …

Liquid biopsy is a valuable precision oncology tool that is increasingly used as a non-
invasive approach to identify biomarkers, detect resistance mutations, monitor disease …

Lung cancer is one of the malignant tumors that seriously threaten human health worldwide,
while the covid-19 virus has become people's nightmare after the coronavirus pandemic …

Stereotactic body radiation therapy (SBRT) offers excellent local control of early-stage non-
small cell lung cancer (NSCLC), but there currently is a need for tolerable systemic therapy …

Ethnopharmacological relevance Circulating tumor cells (CTCs) play an important role in
tumor metastasis and may be a target for metastasis prevention. The traditional Chinese …

Simple Summary Immunotherapy with immune checkpoint inhibitors has recently brought a
paradigm shift in the treatment of non-small cell lung cancer (NSCLC), but until now, most …

Immune checkpoint inhibitors (ICIs) have emerged as one of the main new therapeutic
options for advanced non-small cell lung cancer (NSCLC) patients. Even though they …